 Mark Greenwald
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 4 | 2023 | 179 | 0.870 |
Why?
| | Laser Coagulation | 3 | 2019 | 77 | 0.800 |
Why?
| | Bevacizumab | 3 | 2019 | 167 | 0.800 |
Why?
| | Angiogenesis Inhibitors | 3 | 2019 | 237 | 0.740 |
Why?
| | Fluorescein Angiography | 3 | 2019 | 189 | 0.540 |
Why?
| | Retinoblastoma | 6 | 2008 | 42 | 0.530 |
Why?
| | Lens Implantation, Intraocular | 4 | 2002 | 80 | 0.470 |
Why?
| | Oculomotor Muscles | 4 | 2015 | 84 | 0.340 |
Why?
| | Cataract | 6 | 2007 | 238 | 0.340 |
Why?
| | Cataract Extraction | 5 | 2007 | 119 | 0.320 |
Why?
| | Aphakia, Postcataract | 2 | 1999 | 13 | 0.290 |
Why?
| | Eye Neoplasms | 3 | 1997 | 30 | 0.270 |
Why?
| | Retinal Neoplasms | 3 | 2008 | 37 | 0.270 |
Why?
| | Esotropia | 4 | 2003 | 27 | 0.270 |
Why?
| | Strabismus | 5 | 2015 | 71 | 0.270 |
Why?
| | Eyeglasses | 3 | 2006 | 24 | 0.240 |
Why?
| | Visual Acuity | 9 | 2008 | 489 | 0.230 |
Why?
| | Hyperopia | 2 | 2003 | 19 | 0.200 |
Why?
| | Lens Capsule, Crystalline | 2 | 2002 | 13 | 0.200 |
Why?
| | Hyperthermia, Induced | 2 | 2008 | 121 | 0.190 |
Why?
| | Myopia | 2 | 2003 | 59 | 0.190 |
Why?
| | Refractive Errors | 1 | 2003 | 36 | 0.190 |
Why?
| | Amblyopia | 4 | 2006 | 60 | 0.180 |
Why?
| | Eyelids | 2 | 2013 | 41 | 0.180 |
Why?
| | Infant | 18 | 2019 | 10039 | 0.170 |
Why?
| | Intravitreal Injections | 2 | 2019 | 71 | 0.170 |
Why?
| | Carboplatin | 3 | 2008 | 160 | 0.160 |
Why?
| | Barotrauma | 1 | 1999 | 4 | 0.150 |
Why?
| | Biological Products | 1 | 2022 | 252 | 0.150 |
Why?
| | Eye Injuries | 2 | 1999 | 53 | 0.140 |
Why?
| | Play and Playthings | 1 | 1999 | 35 | 0.140 |
Why?
| | Contact Lenses, Extended-Wear | 1 | 1998 | 1 | 0.140 |
Why?
| | Orbital Fractures | 2 | 1989 | 14 | 0.140 |
Why?
| | Etoposide | 2 | 2008 | 167 | 0.140 |
Why?
| | Skull Fractures | 2 | 1989 | 35 | 0.140 |
Why?
| | Adaptation, Ocular | 1 | 1997 | 6 | 0.140 |
Why?
| | Lens Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Eye Infections, Fungal | 1 | 2017 | 19 | 0.130 |
Why?
| | Candidiasis | 1 | 2017 | 64 | 0.130 |
Why?
| | Candida albicans | 1 | 2017 | 61 | 0.130 |
Why?
| | Endophthalmitis | 1 | 2017 | 45 | 0.130 |
Why?
| | Abscess | 1 | 2017 | 75 | 0.120 |
Why?
| | Facial Muscles | 2 | 2013 | 6 | 0.120 |
Why?
| | Cyclosporine | 1 | 1997 | 265 | 0.120 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2015 | 14 | 0.120 |
Why?
| | Lens, Crystalline | 1 | 2017 | 136 | 0.110 |
Why?
| | Wounds, Nonpenetrating | 1 | 1999 | 316 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 1997 | 2197 | 0.110 |
Why?
| | Refraction, Ocular | 3 | 2019 | 47 | 0.110 |
Why?
| | Child, Preschool | 16 | 2019 | 11799 | 0.110 |
Why?
| | Vision, Binocular | 2 | 1998 | 47 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2023 | 771 | 0.110 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2015 | 90 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1135 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 1958 | 0.100 |
Why?
| | Humans | 39 | 2023 | 144957 | 0.100 |
Why?
| | Cryotherapy | 2 | 2008 | 21 | 0.100 |
Why?
| | Tendons | 1 | 2013 | 129 | 0.090 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2008 | 58 | 0.090 |
Why?
| | Infant, Premature | 3 | 2023 | 611 | 0.080 |
Why?
| | Pseudophakia | 3 | 2002 | 22 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 1768 | 0.080 |
Why?
| | Infant, Newborn | 8 | 2023 | 6434 | 0.080 |
Why?
| | Corneal Diseases | 2 | 2001 | 46 | 0.080 |
Why?
| | Female | 23 | 2022 | 78376 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2019 | 17101 | 0.080 |
Why?
| | Visual Fields | 2 | 1993 | 115 | 0.080 |
Why?
| | Child | 15 | 2007 | 22657 | 0.080 |
Why?
| | Male | 17 | 2022 | 72406 | 0.070 |
Why?
| | Laser Therapy | 2 | 2008 | 135 | 0.070 |
Why?
| | Toxoplasmosis, Congenital | 1 | 2007 | 2 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2008 | 1268 | 0.070 |
Why?
| | Podophyllotoxin | 1 | 2007 | 8 | 0.070 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2007 | 26 | 0.060 |
Why?
| | Accommodation, Ocular | 2 | 2003 | 15 | 0.060 |
Why?
| | Encephalocele | 1 | 1987 | 12 | 0.060 |
Why?
| | Retinal Hemorrhage | 1 | 1986 | 21 | 0.060 |
Why?
| | Sensory Deprivation | 1 | 2006 | 17 | 0.060 |
Why?
| | Neoplasms, Second Primary | 1 | 2007 | 100 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2007 | 177 | 0.060 |
Why?
| | Vitrectomy | 3 | 2003 | 73 | 0.060 |
Why?
| | Retina | 2 | 1989 | 324 | 0.050 |
Why?
| | Fundus Oculi | 3 | 1996 | 89 | 0.050 |
Why?
| | Vision Tests | 1 | 1983 | 22 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 826 | 0.050 |
Why?
| | Vision, Ocular | 1 | 1983 | 47 | 0.050 |
Why?
| | Reflex, Pupillary | 1 | 1983 | 6 | 0.050 |
Why?
| | Reflex, Abnormal | 1 | 1983 | 8 | 0.050 |
Why?
| | Eye Enucleation | 2 | 2008 | 14 | 0.050 |
Why?
| | Afferent Pathways | 1 | 1983 | 46 | 0.050 |
Why?
| | Anisometropia | 1 | 2003 | 18 | 0.050 |
Why?
| | Contact Lenses | 1 | 2003 | 12 | 0.050 |
Why?
| | Astigmatism | 1 | 2003 | 17 | 0.050 |
Why?
| | Keratotomy, Radial | 1 | 2003 | 10 | 0.050 |
Why?
| | Eye | 1 | 1983 | 109 | 0.050 |
Why?
| | Retinal Detachment | 1 | 2003 | 73 | 0.050 |
Why?
| | Mucolipidoses | 1 | 2001 | 9 | 0.040 |
Why?
| | Inclusion Bodies | 1 | 2001 | 27 | 0.040 |
Why?
| | Endothelium, Corneal | 1 | 2001 | 19 | 0.040 |
Why?
| | Adolescent | 10 | 2007 | 22453 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 683 | 0.040 |
Why?
| | Child Abuse | 1 | 1986 | 551 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 557 | 0.040 |
Why?
| | Iris Diseases | 1 | 1999 | 7 | 0.040 |
Why?
| | Marfan Syndrome | 1 | 1999 | 46 | 0.040 |
Why?
| | Vision, Low | 1 | 2019 | 17 | 0.040 |
Why?
| | Disease Progression | 2 | 2008 | 2852 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 975 | 0.040 |
Why?
| | Treatment Outcome | 5 | 2008 | 11695 | 0.040 |
Why?
| | Administration, Ophthalmic | 1 | 2019 | 16 | 0.040 |
Why?
| | Public Health | 1 | 2022 | 566 | 0.030 |
Why?
| | Cerebral Palsy | 1 | 2019 | 132 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1077 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2017 | 149 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2008 | 1141 | 0.030 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 111 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1996 | 222 | 0.030 |
Why?
| | Remission Induction | 1 | 1996 | 308 | 0.030 |
Why?
| | Time Factors | 3 | 2019 | 7183 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1996 | 423 | 0.030 |
Why?
| | Hypothermia, Induced | 1 | 1996 | 96 | 0.030 |
Why?
| | Hearing Loss | 1 | 2019 | 247 | 0.030 |
Why?
| | Lenses, Intraocular | 1 | 1995 | 49 | 0.030 |
Why?
| | Follow-Up Studies | 3 | 2002 | 5417 | 0.030 |
Why?
| | Recovery of Function | 1 | 1999 | 710 | 0.030 |
Why?
| | Age Factors | 3 | 2006 | 3335 | 0.030 |
Why?
| | Risk Factors | 3 | 2023 | 10792 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1695 | 0.030 |
Why?
| | Orbit | 2 | 2011 | 64 | 0.030 |
Why?
| | Intraocular Pressure | 1 | 1995 | 328 | 0.020 |
Why?
| | Blepharoptosis | 1 | 2013 | 12 | 0.020 |
Why?
| | Fasciotomy | 1 | 2013 | 23 | 0.020 |
Why?
| | Cranial Nerve Neoplasms | 1 | 1993 | 7 | 0.020 |
Why?
| | Incontinentia Pigmenti | 1 | 1992 | 3 | 0.020 |
Why?
| | Neurofibromatosis 1 | 1 | 1993 | 54 | 0.020 |
Why?
| | Optic Nerve Diseases | 1 | 1993 | 49 | 0.020 |
Why?
| | Cadaver | 1 | 2013 | 304 | 0.020 |
Why?
| | Connective Tissue | 1 | 2011 | 39 | 0.020 |
Why?
| | Retinal Diseases | 1 | 1992 | 101 | 0.020 |
Why?
| | Klinefelter Syndrome | 1 | 1992 | 69 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 4 | 1989 | 2738 | 0.020 |
Why?
| | Ligaments | 1 | 2011 | 75 | 0.020 |
Why?
| | Stevens-Johnson Syndrome | 1 | 1989 | 37 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7191 | 0.020 |
Why?
| | Adult | 5 | 2011 | 40506 | 0.020 |
Why?
| | Visual Field Tests | 1 | 1989 | 32 | 0.020 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 1989 | 7 | 0.020 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 1989 | 29 | 0.020 |
Why?
| | Orbital Neoplasms | 1 | 1989 | 27 | 0.020 |
Why?
| | Glioma | 1 | 1993 | 426 | 0.020 |
Why?
| | Pyrimethamine | 1 | 2007 | 3 | 0.020 |
Why?
| | Sulfadiazine | 1 | 2007 | 6 | 0.020 |
Why?
| | Antiprotozoal Agents | 1 | 2007 | 15 | 0.020 |
Why?
| | Blindness | 1 | 2008 | 52 | 0.020 |
Why?
| | Leucovorin | 1 | 2007 | 101 | 0.020 |
Why?
| | Teratoma | 1 | 1989 | 120 | 0.020 |
Why?
| | Postoperative Care | 1 | 1989 | 288 | 0.020 |
Why?
| | Botulinum Toxins | 1 | 1987 | 46 | 0.020 |
Why?
| | Injections | 1 | 1987 | 197 | 0.020 |
Why?
| | Preoperative Care | 1 | 1989 | 380 | 0.020 |
Why?
| | Electroretinography | 1 | 1986 | 50 | 0.020 |
Why?
| | Suture Techniques | 1 | 1987 | 131 | 0.020 |
Why?
| | Accidental Falls | 1 | 1989 | 222 | 0.010 |
Why?
| | Forecasting | 1 | 1987 | 391 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 1048 | 0.010 |
Why?
| | Ocular Physiological Phenomena | 1 | 1983 | 10 | 0.010 |
Why?
| | Evoked Potentials, Visual | 1 | 1983 | 42 | 0.010 |
Why?
| | Cats | 1 | 1983 | 228 | 0.010 |
Why?
| | Visual Cortex | 1 | 1983 | 84 | 0.010 |
Why?
| | Aged | 2 | 2013 | 25947 | 0.010 |
Why?
| | Keratoplasty, Penetrating | 1 | 2001 | 9 | 0.010 |
Why?
| | Visual Perception | 1 | 1983 | 183 | 0.010 |
Why?
| | Vacuoles | 1 | 2001 | 38 | 0.010 |
Why?
| | Databases, Factual | 1 | 2007 | 1486 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1983 | 902 | 0.010 |
Why?
| | Incidence | 1 | 2007 | 2883 | 0.010 |
Why?
| | Corneal Edema | 1 | 1999 | 4 | 0.010 |
Why?
| | Miotics | 1 | 1999 | 6 | 0.010 |
Why?
| | Pilocarpine | 1 | 1999 | 16 | 0.010 |
Why?
| | Safety | 1 | 2002 | 356 | 0.010 |
Why?
| | Child Development | 1 | 1983 | 484 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 8279 | 0.010 |
Why?
| | Middle Aged | 2 | 2011 | 35928 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 5965 | 0.010 |
Why?
| | Prospective Studies | 1 | 2008 | 7997 | 0.010 |
Why?
| | Color Perception | 1 | 1993 | 25 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1983 | 4569 | 0.010 |
Why?
| | Aging | 1 | 1983 | 1966 | 0.010 |
Why?
| | Vitreous Hemorrhage | 1 | 1989 | 10 | 0.000 |
Why?
| | Hyphema | 1 | 1989 | 6 | 0.000 |
Why?
| | Neoplasm Invasiveness | 1 | 1989 | 509 | 0.000 |
Why?
| | Genotype | 1 | 1992 | 1835 | 0.000 |
Why?
| | Length of Stay | 1 | 1989 | 1337 | 0.000 |
Why?
| | Animals | 1 | 1983 | 38109 | 0.000 |
Why?
|
|
Greenwald's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|